Stock To Watch: Rocket Pharma On Track

Rocket Pharmaceuticals, Inc. (RCKT), on Sunday, reported positive preliminary results from its phase I study of commercial-grade gene therapy RP-L102 "Process B" for Fanconi Anemia (FA) at the 61st annual meeting of American Society of Hematology (ASH).

Fanconi anemia is a rare genetic disorder, that mainly affects the bone marrow resulting in the decreased production of all types of blood cells.

The data were that of two pediatric patients of age 5 and 6 years who were treated with "Process B" RP-L102 prior to the development of severe bone marrow failure.
Treatment with 'Process B' RP-L102 at four to six months post-infusion showed early signs of engraftment and bone marrow restoration, noted the Company. Previously declining blood cell counts have been stabilized or even increased within six months of therapy.

"Process B" trial incorporates higher cell doses, transduction enhancers, and commercial-grade vector manufacturing and cell processing. No safety or tolerability issues have been reported.

The company expects to present additional long-term follow-up data from these patients in the first half of 2020.

A global registrational phase II study of "Process B" RP-L102 for Fanconi Anemia is currently underway, with primary endpoint of bone marrow MMC-resistance. The trial is expected to enroll five patients in the U.S. and five patients in Europe.

RCKT closed Friday's trading at $22.36, up 2.66%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is looking to set a new framework to further improve and maintain the supply of infant formula to ensure that American consumers have access to safe and nutritious infant formula. Infant formula is an essential food product that is the sole source of nutrition for many babies in the U.S. Amazon has unveiled millions of deals worldwide that will be available during its upcoming Prime Day extravaganza. The 48-hour shopping event for Prime members kicks off July 12 at 3 a.m. EDT, offering deals of up to 79% off across various categories. These include electronics, devices, toys, beauty, fashion, and home, from top national brands and small businesses. Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores.
Follow RTT